On June 10, 2025, D. Boral Capital has reiterated its 'Buy' rating for Anixa Biosciences (ANIX, Financial). The analyst covering the stock, Jason Kolbert, confirmed that the price target for ANIX remains stable at $10.00 USD.
This consistent outlook reflects the firm's maintained confidence in Anixa Biosciences, as both the current and prior ratings have been upheld without any adjustments in the price target. Investors looking at ANIX can note that the company's financial outlook remains positive according to this latest assessment.
There has been no change in the percentage from the previous target, ensuring that the price target and rating stand identical to prior evaluations. The stability in the rating signifies a continued endorsement from D. Boral Capital for potential investors interested in ANIX.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Anixa Biosciences Inc (ANIX, Financial) is $9.00 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 164.71% from the current price of $3.40. More detailed estimate data can be found on the Anixa Biosciences Inc (ANIX) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Anixa Biosciences Inc's (ANIX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
